Background Solid-pseudopapillary neoplasm (SPN), a rare neoplasm of the pancreas, frequently harbors mutations in exon 3 of the cadherin-associated protein beta 1 (CTNNB1) gene. Here, we analyzed SPN tissue for CTNNB1 mutations by deep sequencing using next-generation sequencing (NGS). Methods Tissue samples from 7 SPNs and 31 other pancreatic lesions (16 pancreatic ductal adenocarcinomas (PDAC), 11 pancreatic neuroendocrine tumors (PNET), 1 acinar cell carcinoma, 1 autoimmune pancreatitis lesion, and 2 focal pancreatitis lesions) were analyzed by NGS for mutations in exon 3 of CTNNB1. Results A single-base-pair missense mutations in exon 3 of CTNNB1 was observed in all 7 SPNs and in 1 of 11 PNET samples. However, mutations were not observed in the tissue samples of any of the 16 PDAC or other four pancreatic disease cases. The variant frequency of CTNNB1 ranged from 5.4 to 48.8 %.
Introduction
Solid-pseudopapillary neoplasm (SPN) of the pancreas is a rare tumor that accounts for 0.2-2.7 % of all pancreatic tumors [1] , predominantly seen in young female patients. It was first described by Frantz [2] in 1959. SPN of the pancreas is characterized by low-grade malignant potential, with an incidence of metastasis of 15 %, and tends to have a favorable prognosis with surgical resections, considered the standard of care, with a 5-year overall survival rate of more than 95 % [1, 3, 4] .
b-Catenin is a submembranous component of the cadherin-mediated cell adhesion system and acts as a downstream transcriptional activator of Wnt signaling. Under normal conditions, cytoplasmic b-catenin is expressed at a low level. Phosphorylation of both adenomatous polyposis coli (APC) and axin by glycogen synthase kinase-3b (GSK-3b) enhances b-catenin binding to the APC-axin complex and targets the protein for ubiquitination and proteasomal degradation [5] . In the nucleus, b-catenin forms complexes with proteins such as Tcf and Lef-1 [6] , and activates the transcription of several oncogenic genes including c-myc and cyclin D1.
Mutations in exon 3 of the b-catenin gene (also called CTNNB1) are reported in approximately 83-100 % [7] [8] [9] [10] [11] [12] of surgically resected SPN samples. Accordingly, these mutations are considered a unique genetic characteristic of SPNs, differentiating them from other pancreatic tumors.
Direct sequencing is considered the gold standard for mutational analysis. However, it is difficult to detect a small proportion of mutant genes using this method. Recently, next-generation sequencing (NGS) has enabled the evaluation of multiple genes for genomic alterations in a single tumor, with high accuracy [13] . Less frequent mutations can also be detected if deep sequencing is performed.
Several studies have described the usefulness of EUSguided fine-needle aspiration (EUS-FNA) for diagnosing SPNs [14] [15] [16] [17] [18] . SPNs could be seen as well-demarcated, hypoechoic, solid masses that sometimes coexist with cystic lesions and/or calcification on EUS. Accuracy of preoperative SPN diagnosis by EUS-FNA is reported to be 75-100 % [17, 18] ; however, diagnosis by EUS-FNA is sometimes difficult because of interpretative, sampling, and misclassification errors or insufficient material for immunostaining [19] . In addition, EUS-FNA samples sometimes contain tumor cells that are too small to use for sequencing analysis by polymerase chain reaction (PCR)-based direct sequencing.
In the present study, we analyzed CTNNB1 mutations using EUS-FNA samples and NGS. To the best of our knowledge, this is the first report of CTNNB1 mutational analysis using EUS-FNA samples and NGS.
Methods

Samples
Thirty-eight samples were tested: 7 SPNs, 16 pancreatic ductal adenocarcinomas (PDAC), 11 pancreatic neuroendocrine tumors (PNET), and 4 other pancreatic lesions. Non-SPN samples were used as controls. Samples were obtained by either EUS-FNA (n = 35) or surgery (n = 3) at Hokkaido University Hospital, Sapporo, Japan, between December 2008 and June 2013. All participants provided written informed consent, and the ethics committee at Hokkaido University Graduate School of Medicine approved the study.
EUS-FNA procedure EUS-FNA was performed by a single experienced endoscopist (H.K.) using a curvilinear echoendoscope (GF-UCT240-AL5; Olympus Medical Systems Co., Tokyo, Japan) and 22-gauge needles (Echotip Ultra; Cook Japan, Tokyo, Japan) with the patient under conscious sedation. Briefly, the lesions were visualized by EUS, and the needle was advanced into the lesion through the gastric or duodenal wall. The central stylet was removed, and a syringe was attached to the needle hub to apply negative suction pressure. The needle was then moved back and forth within the lesion at least 10 times and then removed through the scope, before the stylet was re-inserted into the needle. The specimen obtained by aspiration was placed on a slide, airdried, alcohol-fixed, and used to prepare smears that were stained using the rapid Romanowsky technique for quick interpretation and assessment of sample adequacy (DiffQuik stain; Kokusai Shiyaku, Kobe, Japan). Diff-Quik staining was performed on all specimens by an experienced cytotechnologist (K.M.). Cytological and histological diagnoses were made for the specimens obtained by EUS-FNA [20, 21] .
DNA extraction, PCR, and sequencing analysis of CTNNB1
The FNA samples were stored in RNAlater (Life Technologies Corporation, Carlsbad, CA). Genomic DNA and RNA were extracted from samples using an AllPrep Ò DNA/RNA/Protein mini kit (Qiagen, Inc., Valencia, CA) according to the manufacturer's instructions. Three PNET samples were obtained from surgery. Tumor samples were fixed in 10 % buffered formalin and embedded in paraffin for microdissection of the tumor tissue. Genomic DNA was semi-automatically extracted using a QIAamp Ò DNA FFPE tissue kit (Qiagen) and QIAcube Ò (Qiagen) according to the manufacturer's instructions. Total RNA concentration was determined by spectrophotometer (NanoDrop2000/2000c; Thermo Scientific, Tokyo, Japan), and 5 lg total RNA were reverse transcribed using SuperScript Ò II Reverse Transcriptase (Invitrogen, Carlsbad, CA). Approximately 100 ng of each genomic DNA sample were used for PCR. Genomic DNA was amplified by semi-nested PCR, using the first and second primer pairs (Table 1) . Primers for the second PCR contained adaptors and barcodes for further NGS analysis, and the PCR products were bidirectionally read by NGS. These primers were designed to amplify a 228-bp DNA fragment of the entire exon 3 of CTNNB1. The thermal cycler (Life Technologies) was programmed as follows: initial denaturation at 94°C for 7 min and 35 amplification cycles for each PCR. Each amplification cycle comprised denaturation at 94°C for 15 s, annealing at 58°C for 15 s, and elongation at 72°C for 30 s. The last cycle was followed by a final extension at 72°C for 5 min. The PCR products were verified by agarose gel electrophoresis. The band of the expected size was excised and purified using a QIAquick Ò Gel Extraction kit (Qiagen). The concentration and amplicon size of the barcoded libraries were determined by using an Agilent 2100 Bioanalyzer and Agilent DNA 1000 kit (Agilent Technologies, Inc., Santa Clara, CA).
They were pooled and mixed with Ion Spheres TM particles for emulsion PCR using the Ion OneTouch TM System (Life Technologies) with an Ion OneTouch The PCR products were also submitted to direct sequencing using ABI Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and the primers used for PCR. Sequencing of each PCR product was performed with an ABI PRISM TM 310 Genetic Analyzer (Applied Biosystems). Each mutation was verified in both sense and antisense directions.
Results
Clinicopathological features
The clinicopathological features of the 38 patients are summarized in Table 2 . The patient population comprised 24 women and 14 men, with ages ranging from 13 to 81 years (median 63.5 years). SPNs tended to be located in the pancreatic body and tail rather than in the pancreatic head. Other tumors involved all parts of the pancreas and were evenly distributed. Tumor sizes ranged from 8 to 95 mm at the greatest diameter (median 23 mm).
The types of surgical procedures were as follows: three subtotal stomach-preserving pancreaticoduodenectomies, two duodenum-preserving pancreas head resections, seven distal pancreatectomies (four with splenectomy and one with spleen and left adrenal gland resection), one partial pancreatectomy, and one left nephrectomy with metastatic lymph node tumor resection. Two patients with PDAC had resectable disease, whereas the other cases were unresectable.
The histological features of the specimens with SPN obtained by EUS-FNA are shown in Fig. 1 . In most cases, SPN showed typical findings, but in case 7, SPN was not easily distinguished from PNET. Immunohistochemical staining was performed for SPN and PNET samples. Two SPNs showed a few chromogranin A-positive cells, five of seven SPNs showed immunoreactivity against Synaptophysin, and five SPNs showed nuclear staining for bcatenin. All PNET samples were positive for chromogranin A and synaptophysin, and none showed nuclear immunoreactivity against b-catenin.
Genomic DNA and RNA were extracted from FNA samples in 35 patients. For three PNET patients (Case 24, 25 and 26), surgically resected specimens were used to obtain DNA.
Mutations in exon 3 of CTNNB1 by NGS All seven SPNs showed a single-base-pair missense mutation in exon 3 of CTNNB1. Neither the PDAC nor acinar cell carcinoma cases showed a CTNNB1 exon 3 mutation. Of the 11 PNETs, a single-base-pair missense mutation was detected in one sample. Variant frequency and coverage ranged from 5.4 to 48.8 % and from 4,490 to Table 3 . For the control samples, the average base coverage depth ranged from 113 to 8,027 (median 7,312).
Mutations in exon 3 of CTNNB1 by direct sequencing Direct sequencing was performed using samples that had mutations detected by NGS. One SPN case with mutation was not able to perform direct sequencing due to an insufficient amount of the sample. Only one of the seven cases could detect mutation by direct sequencing, as shown also in Table 3 .
Discussion
Mutations in exon 3 of CTNNB1 have been reported in various tumors, including those of the colon [22] , prostate [23] , endometrium [24] , and liver [25] . In SPN, cytoplasmic/nuclear immunoreactivity for bcatenin was detected during the systemic immunohistochemical study of pediatric tumors [7] . After the first report by Tanaka et al. [7] , mutations in exon 3 of CTNNB1 have been reported in 83-100 % [7] [8] [9] [10] [11] [12] of SPNs. Previous studies used microdissected tumor tissue from formalinfixed, paraffin-embedded blocks obtained by surgery to extract genomic DNA. Single-base-pair missense mutations in codons 32, 33, 34, 37, and 41, and 12-base-pair deletion corresponding to codons 28-32 have been documented. Serine 33 and 37 as well as threonine 41 are the sites for GSK-3 b phosphorylation [26] . Codons 32 and 34 serve as crucial elements of the DSGUXS motif to create a recognition site for b-TrCP and subsequent ubiquitin-mediated proteasomal degradation [27, 28] . Both mechanisms lead to the abnormal stabilization of b-catenin and its resultant aberrant nuclear expression in SPNs.
In the present study, eight cases showed CTNNB1 mutations. Mutations were detected in codons 32, 37, and 41, consistent with the findings of previous reports [7] [8] [9] [10] [11] [12] . To the best of our knowledge, this is the first report of mutational analysis for CTNNB1 using EUS-FNA samples and NGS. Of the eight cases, seven were of SPN and one was of PNET. That PNET was diagnosed by the typical radiologic finding (a hypervascular round mass that was best visualized in the arterial contrast enhancement phase on computed tomography) and immunohistochemical staining (positive chromogranin A and synaptophysin immunostaining, negative CD56 staining, and no nuclear b-catenin accumulation) of an EUS-FNA sample. The patient did not undergo surgery because of the small size (9.6 9 5.4 mm) and low-grade malignant potential of the lesion, which was diagnosed on the basis of EUS-FNA specimen analysis (Ki-67 index, 1-2 %). Several assays can be performed to detect genetic mutations, such as hematoxylin and eosin and immunohistochemical staining, fluorescence in-situ hybridization, polymerase chain reaction, and direct sequencing. Although direct sequencing is considered the gold standard, it lacks the ability to detect small proportions of mutant genes and technical experience is essential for accurate result interpretation. In one study, mutant DNA had to account for at least 30 % of wild-type DNA for the detection of mutations by direct sequencing [29] . In our study, mutations caught by NGS could be detected in only one of seven samples by direct sequencing. Our result showed the superiority of NGS in detecting mutations over direct sequencing, as indicated in previous reports. This result suggests the usefulness of FNA specimens for genetic analyses when combined with NGS, since EUS-FNA specimens are usually mixed with blood or tissue in the needle tract.
To date, CTNNB1 mutations have not been reported in PNET. Gerdes et al. [30] previously performed CTNNB1 mutational analysis on 78 PDAC, 33 PNET, and 14 pancreatic cancer cell lines and found no mutations in exon 3 of CTNNB1. Similarly, Liu et al. [10] found no mutations in exon 3 of CTNNB1 in 14 PNET samples. Exome sequence analysis of approximately 18,000 protein-coding Fig. 1 genes of 10 PNET samples was carried out by Jiao et al. [31] to explore the genetic basis of the disease. They reported novel DAXX and ATRX mutations, but mutations in CTNNB1 were not detected. With regard to neuroendocrine tumors in other organs, Kim et al. [32] detected a single-base-pair mutation in one of two thymus neuroendocrine tumors, which resulted in a replacement of isoleucine by serine at codon 35. Another mutation was seen in a cell line of neuroendocrine tumor of midgut (terminal ileum) origin [33] . To explore whether CTNNB1 mutations occur in PNET, we enrolled two more cases of PNET that were diagnosed by surgery, but did not detect any mutations. Further analysis should be performed to determine if CTNNB1 mutations occur in PNET.
One of the most important differential diagnoses of SPN is PNET [16, 34] . Histologically, most SPNs show a solidmonomorphous growth in the peripheral parts of the lesion. In the center, tumor cells form pseudopapillary structures [35] . PNETs are morphologically very similar to SPNs. Immunostaining is useful in differentiating SPNs from PNETs. SPNs specifically express vimentin and CD10 [8, 36] and usually show focal immunoreactivity against synaptophysin, but not for chromogranin A. On the other hand, PNETs usually show diffuse staining for synaptophysin. Strong staining for chromogranin A is observed in differentiated neuroendocrine tumors, NETs, but negative or very mild staining is found in poorly differentiated lesions [37, 38] . b-Catenin localization is also quite different between these two tumor types. SPNs show cytoplasmic and nuclear staining [3, 7] , but PNETs show membranous staining. Accurate diagnosis of SPNs is sometimes difficult with EUS-FNA because of interpretative, sampling, and misclassification errors or insufficient material for immunostaining [19] . In the present study, 1 case of SPN could not be diagnosed pathologically on the basis of EUS-FNA samples. However, the CTNNB1 mutation was detected by NGS, and the patient was diagnosed as having SPN and was scheduled for surgery at the time of reporting.
The current study was limited by two points. First, not all of the mutational analyses were performed prior to the final diagnosis by either EUS-FNA or surgery. Second, being a rare tumor, the sample size was rather small.
Conclusions
Analysis of exon 3 mutations in CTNNB1 by NGS is feasible using EUS-FNA samples. All SPN cases showed CTNNB1 mutations. Further exploration of mutational analyses including CTNNB1 in neuroendocrine tumors is required to determine the genetic alterations of PNET.
